ACRS
Aclaris Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$3.97Close
$478.4MMarket cap
$2.13 – $6.5352-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Far from its high 39% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
39%
1wk
up 5.9%
price change
1mo
down 24.5%
price change
12-month return
up 59%
market up 11% ·
its own up 59%
F-score
3 / 9
Weak
Altman Z
-4.46
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.6×
price / book
Earnings yield
down 16.7%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
down 58%
year on year
EPS growth
—
latest quarter
Sales growth
down 8%
latest quarter · -46 pts
ROE
down 50%
return on equity
Free cash margin
down 603%
-$47.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
7.6%
$0.30 a day · 2×ATR $3.37
RS
50 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.82
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 11.7% over the year, from 108m to 120m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 85.1% to 73.3%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 58.2% over the year, from $18.7M to $7.8M.
Last reported
Oct 27, 2026
Last shock
Oct 1, 2026-16% in one session2.2× volumeno filing matched-10% since
Financials
- Gross 73%
- Net -830%
- Free cash -603%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.5M | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M |
| Gross margin | 21% | 30% | 86% | 89% | 85% | 73% |
| Operating income | -$50.9M | -$89.7M | -$89.9M | -$97.4M | -$141.9M | -$76.4M |
| Net income | -$51.0M | -$90.9M | -$86.9M | -$88.5M | -$132.1M | -$64.9M |
| Net margin | -787% | -1344% | -292% | -283% | -705% | -830% |
| Earnings per share | -$1.20 | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 |
| Free cash flow | -$39.1M | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.2M |
| Free cash margin | -603% | -776% | -229% | -255% | -108% | -603% |
| Cash | $22.1M | $27.3M | $45.3M | $39.9M | $24.6M | $20.0M |
| Long-term debt | $10.7M | — | — | — | — | — |
| Shareholders' equity | $37.6M | $197.3M | $197.6M | $157.2M | $155.6M | $103.1M |
| Shares outstanding | 45.11m | 61.23m | 66.69m | 70.89m | 107.85m | 120.50m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Material agreement ↗ |
| Oct 27, 2026 | Results · Regulation FD · Other events ↗ |
| Aug 6, 2026 | Material agreement ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 28, 2026 | Regulation FD · Other events ↗ |
| Mar 11, 2026 | Regulation FD ↗ |
| Mar 10, 2026 | Regulation FD ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Jan 6, 2026 | Regulation FD · Other events ↗ |